Sells adjustable lenses and light-delivery devices that let eye surgeons customize patients’ vision after cataract surgery, to surgery centers, hospitals and physician practices.
10-K for FY2025, filed Feb 25, 2026
RxSight sells to surgery centers, hospitals and physician practices through its U.S. direct sales and account teams; international customers include distributors.
No. It lost $38.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$16.2MView ↗
8-K, filed Aug 5, 2026
In connection with the leadership transition, withdrew 2026 guidance; will resume formal guidance in early 2027View ↗
8-K, filed Jul 15, 2026
On July 13, 2026, the Board of Directors (the “Board”) of RxSight, Inc. (the “Company”) appointed Aziz Mottiwala to serve as the Company’s…View ↗
8-K, filed Jul 6, 2026
On June 30, 2026 (the “Effective Date”), we entered into a License, Collaboration and Development Agreement (the “RxSight-Alcon…View ↗
Competes with Alcon and Johnson & Johnson
10-K for FY2025, filed Feb 25, 2026From a commercial perspective, we believe our primary competitors in the cataract U.S. IOL market are premium IOL providers, including…View ↗
Loading...